COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8 million in cash TORONTO, ONTARIO, Aug. 13, 2024 (G

By: financialpost.com

Aug 13 2024
0
0 Views

Cash and cash equivalents Read More

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Muck Rack Named to Inc. 5000 for Third Consecutive Year

Altman-Backed Startup Opens Largest US Facility to Pull Carbon From Air

Crescent Innovations reports strong interest in asset sale

US wholesale inflation cooled in July in sign that price pressures are continuing to ease

Pacific Defense Announces US Army CMFF Program Team

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Goliath Resources Receives $2,000,000 Order From Strategic Singapore Based Global Commodity Group And The Previously Announced Non-Brokered Private Placement Has Been Increased From $3,000,000 Up To $6,500,000

Home Depot trims guidance with anxiety about the broader economy up among contractors and homeowners

Kobo Resources Reports Final Gold Assay Results from its Initial Diamond Drill Program Highlighted by 14 m at 2.91 g/t Au and 6 m at 5.47 g/t Au from the Jagger Zone

Algernon Pharmaceuticals Announces Increase to Private Placement

Euna Solutions Recognized as Government Technology Company of the Year in 2024 Stevie Awards for Technology Excellence

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Get Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Related